Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Idiopathic Myelofibrosis
NCT00387426Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in primary myelofibrosis (PMF), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Objective Clinical Response to Sunitinib Therapy at 12 weeks. Started Sep 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT00387426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387426.